Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  2. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). … An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … to a different glycosylation pattern.

  4. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  5. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. … It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 Substrates
  6. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    Zidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2. … [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available

  7. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes … Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

  8. Drug

    Tovorafenib

    go.drugbank.com/drugs/DB15266
    ApprovedInvestigational

    Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. … [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 Inducers
  9. Drug

    Hydrocortisone aceponate

    go.drugbank.com/drugs/DB14538
    InvestigationalVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  10. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.